SLC12A5 and metabolic disease: Consequently, KCC2 has been proposed as a feasible therapeutic target for neuronal disorders, including neuropathic pain, epileptic seizure, neurological trauma, and metabolic diseases, in which KCC2 dysfunction might be the underlying cause [13,16,17].